Literature DB >> 31288931

Pediatric pulse oximetry-based OSA screening at different thresholds of the apnea-hypopnea index with an expression of uncertainty for inconclusive classifications.

Ainara Garde1, Xenia Hoppenbrouwer2, Parastoo Dehkordi3, Guohai Zhou4, Aryannah Umedaly Rollinson5, David Wensley6, Guy A Dumont3, J Mark Ansermino5.   

Abstract

BACKGROUND: Assessments of pediatric obstructive sleep apnea (OSA) are underutilized across Canada due to a lack of resources. Polysomnography (PSG) measures OSA severity through the average number of apnea/hypopnea events per hour (AHI), but is resource intensive and requires a specialized sleep laboratory, which results in long waitlists and delays in OSA detection. Prompt diagnosis and treatment of OSA are crucial for children, as untreated OSA is linked to behavioral deficits, growth failure, and negative cardiovascular consequences. We aim to assess the performance of a portable pediatric OSA screening tool at different AHI cut-offs using overnight smartphone-based pulse oximetry.
MATERIAL AND METHODS: Following ethics approval and informed consent, children referred to British Columbia Children's Hospital for overnight PSG were recruited for two studies including 160 and 75 children, respectively. An additional smartphone-based pulse oximeter sensor was used in both studies to record overnight pulse oximetry [SpO2 and photoplethysmogram (PPG)] alongside the PSG. Features characterizing SpO2 dynamics and heart rate variability from pulse peak intervals of the PPG signal were derived from pulse oximetry recordings. Three multivariate logistic regression screening models, targeted at three different levels of OSA severity (AHI ≥ 1, 5, and 10), were developed using stepwise-selection of features using the Bayesian information criterion (BIC). The "Gray Zone" approach was also implemented for different tolerance values to allow for more precise detection of children with inconclusive classification results.
RESULTS: The optimal diagnostic tolerance values defining the "Gray Zone" borders (15, 10, and 5, respectively) were selected to develop the final models to screen for children at AHI cut-offs of 1, 5, and 10. The final models evaluated through cross-validation showed good accuracy (75%, 82% and 89%), sensitivity (80%, 85% and 82%) and specificity (65%, 79% and 91%) values for detecting children with AHI ≥ 1, AHI ≥ 5 and AHI ≥ 10. The percentage of children classified as inconclusive was 28%, 38% and 16% for models detecting AHI ≥ 1, AHI ≥ 5, and AHI ≥ 10, respectively.
CONCLUSIONS: The proposed pulse oximetry-based OSA screening tool at different AHI cut-offs may assist clinicians in identifying children at different OSA severity levels. Using this tool at home prior to PSG can help with optimizing the limited resources for PSG screening. Further validation with larger and more heterogeneous datasets is required before introducing in clinical practice.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Mobile health solutions; Oxygen saturation dynamics; Pediatric sleep apnea; Pulse oximetry; Pulse rate variability; Signal analysis

Year:  2018        PMID: 31288931     DOI: 10.1016/j.sleep.2018.08.027

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  2 in total

1.  Assessment of Airflow and Oximetry Signals to Detect Pediatric Sleep Apnea-Hypopnea Syndrome Using AdaBoost.

Authors:  Jorge Jiménez-García; Gonzalo C Gutiérrez-Tobal; María García; Leila Kheirandish-Gozal; Adrián Martín-Montero; Daniel Álvarez; Félix Del Campo; David Gozal; Roberto Hornero
Journal:  Entropy (Basel)       Date:  2020-06-17       Impact factor: 2.524

2.  Use of facial stereophotogrammetry as a screening tool for pediatric obstructive sleep apnea by dental specialists.

Authors:  Nathalia Carolina Fernandes Fagundes; Terry Carlyle; Oyku Dalci; M Ali Darendeliler; Ida Kornerup; Paul W Major; Andrée Montpetit; Benjamin T Pliska; Stacey Quo; Giseon Heo; Carlos Flores Mir
Journal:  J Clin Sleep Med       Date:  2022-01-01       Impact factor: 4.062

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.